We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 788

Injunction preventing use of mark not available where use in the US, and not Canada
  • Borden Ladner Gervais LLP
  • Canada, USA
  • November 2 2016

The Court dismissed the Defendant's motion for an interim andor interlocutory injunction restraining the Plaintiffs, inter alia, from using any


Data protection regulations upheld by Court of Appeal
  • Borden Ladner Gervais LLP
  • Canada
  • December 15 2010

This decision relates to appeals of a decision by the Federal Court, in which the Court dismissed two judicial review applications seeking a declaration that subsection 30(3) of the Food and Drugs Act (the Act) and section C.08.004.1 of the Food and Drug Regulations (the Regulations), relating to data protection, are ultra vires and without legal force and effect


industry news
  • Borden Ladner Gervais LLP
  • Canada, Global
  • April 6 2011

The Management of Drug Submissions Guidance has been revised to include changes resulting from the release of the new Fees in Respect of Drugs and Medical Devices Regulations


Other cases of interest
  • Borden Ladner Gervais LLP
  • Canada
  • March 29 2010

After receiving names of the Defendants’ customers during discovery, the Plaintiff wrote to these customers, advising that they may have relevant evidence and requesting that they not destroy the evidence


AstraZeneca v NovopharmDrug
  • Borden Ladner Gervais LLP
  • Canada
  • May 5 2010

In an action for infringement, the Court of Appeal dismissed AstraZeneca's appeal from a Trial Decision striking out the Statement of Claim


Additional documents not part of appeal
  • Borden Ladner Gervais LLP
  • Canada
  • January 26 2011

Shire brought the within motion to determine the contents of the appeal books, in order to include additional documents that were not before the trial judge


Patent Appeal Board considers solution to problem non-obvious
  • Borden Ladner Gervais LLP
  • Canada
  • September 17 2012

The Examiner rejected the patent application for a system for preparing a schedule for travel on the basis that the claims are obvious


Reynolds Presto Products Inc. v. P.R.S. Mediterranean Ltd., 2013 FCA 119
  • Borden Ladner Gervais LLP
  • Canada
  • May 8 2013

The Court of Appeal has overturned a lower court decision and struck the mark NEOWEB from the register because it is confusing with the earlier


Teva Canada Innovation v. Attorney General of Canada
  • Borden Ladner Gervais LLP
  • Canada
  • May 8 2013

The Patented Medicine Prices Review Board (the PMPRB) ordered Teva to pay the Crown approximately $2.4 million for selling its product at an


Claim to disgorgement of profits denied by Ontario Court of Appeal
  • Borden Ladner Gervais LLP
  • Canada
  • September 18 2013

Apotex appealed in the Ontario Court of Appeal from a partial summary judgment that dismissed its unjust enrichment claim for the disgorgement of the